MARKET

KOD

KOD

Kodiak Sciences Inc.
NASDAQ
23.31
+0.12
+0.52%
After Hours: 23.22 -0.09 -0.39% 18:29 03/16 EDT
OPEN
23.66
PREV CLOSE
23.19
HIGH
24.21
LOW
23.19
VOLUME
355.92K
TURNOVER
--
52 WEEK HIGH
31.18
52 WEEK LOW
1.920
MARKET CAP
1.42B
P/E (TTM)
-5.6593
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KOD last week (0309-0313)?
Weekly Report · 14h ago
Weekly Report: what happened at KOD last week (0302-0306)?
Weekly Report · 03/09 10:07
Analysts’ Opinions Are Mixed on These Healthcare Stocks: US Physical Therapy (USPH) and Kodiak Sciences (KOD)
TipRanks · 03/06 21:10
Weekly Report: what happened at KOD last week (0223-0227)?
Weekly Report · 03/02 10:06
Weekly Report: what happened at KOD last week (0216-0220)?
Weekly Report · 02/23 10:07
First Week of April 17th Options Trading For Kodiak Sciences (KOD)
NASDAQ · 02/20 17:04
Analysts Are Bullish on Top Healthcare Stocks: CervoMed (CRVO), Kodiak Sciences (KOD)
TipRanks · 02/20 15:30
Weekly Report: what happened at KOD last week (0209-0213)?
Weekly Report · 02/16 10:07
More
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Webull offers Kodiak Sciences Inc stock information, including NASDAQ: KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.